COMMUNIQUÉS West-GlobeNewswire
 
      -   
  GENFIT : Issue positive du DSMB à 30 mois, recommandant la poursuite de l'étude clinique de Phase 3 RESOLVE-IT évaluant elafibranor dans la NASH17/12/2018
-   
  Proposed Subscription to Raise $25m and Notice of General Meeting17/12/2018
-   
  NeuroSearch – financial calendar for 201917/12/2018
-   
  Summit Therapeutics Announces Departure of Chief Financial Officer17/12/2018
-   
  Clarification from the Board of Directors and Management of Oasmia Pharmaceutical AB (publ), “Oasmia” due to Per Arwidsson’s and Arwidsro Investment AB’s request for convening an Extraordinary General Meeting17/12/2018
-   
  Verona Pharma Initiates Phase 2 Clinical Trial to Evaluate Dry Powder Inhaler Formulation of RPL554 for Maintenance Treatment of COPD17/12/2018
-   
  Farmako: Biggest non-Canadian investment in Europe to date With Seven-digit Investment by Heartbeat Labs17/12/2018
-   
  Nicox and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize NCX 470 in the Chinese market17/12/2018
-   
  Nicox : signature d'un accord de licence exclusif avec Ocumension Therapeutics pour le développement et la commercialisation de NCX 470 sur le marché chinois17/12/2018
-   
  BIOPHYTIS Strengthens its Senior Management Team and Continues its Expansion in the United States17/12/2018
-   
  VALNEVA Initiates Phase 2 Clinical Development For Its Lyme Disease Vaccine Candidate17/12/2018
-   
  VALNEVA lance la Phase 2 du développement de son vaccin contre la maladie de Lyme17/12/2018
-   
  Atara Biotherapeutics Presents Positive Efficacy and Safety Results for Patients with Epstein-Barr Virus-Associated Leiomyosarcoma (EBV+ LMS)15/12/2018
-   
  BeiGene Announces Updated Phase 1A/1B Data on Tislelizumab Presented at the European Society for Medical Oncology Immuno-Oncology Congress15/12/2018
-   
  Helix BioPharma Corp. Announces Fiscal First Quarter 2019 Results14/12/2018
-   
  Sonoma Pharmaceuticals Announces Management Changes14/12/2018
-   
  Pediapharm annonce le changement de son nom, la consolidation de ses actions et le remboursement de ses débentures14/12/2018
-   
  Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)14/12/2018
-   
  Cannabis Users Drive High, and Crashes Are on the Rise-- CFN Media14/12/2018
Pages